2d illustrations and photos
Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering.
In an SEC filing, Ascentage (AAPG) said it plans to offer 7.3M American Depositary Shares, representing 29.3M ordinary shares. While the company
